cyclopropylmethylscopolamine
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Dec 1, 2009 (NCT01842932)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- Muscarinic acetylcholine receptor M3ANTAGONIST
CHRM3 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
C[N+]1(CC2CC2)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12- Mol. weight
- 358.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2110773 ↗
- ChEMBLCHEMBL2105977 ↗
Also known as
- 3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane, 9-(cyclopropylmethyl)-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, bromide, (7(s)-(1 alpha,2 beta,4 beta,5 alpha,7 beta))-
- cimetropium
- cimetropium
- cimetropium
- cimetropium
- cimetropium
- cimetropium
- cimetropium bromide
- cimetropium bromide
- cimetropium bromide
- cimetropium bromide
- cimetropium bromide
- cimetropium bromide
- cimetropium cation
- cimetropium cation
- cimetropium ion
- cimetropium ion
- cyclopropylmethylscopolamine bromide
- da 3177
- da-3177
- scopolamine n-(cyclopropylmethyl)bromide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01842932 | Phase 4 | Dec 1, 2009 | Ajou University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ajou University | Academic/Hospital | 1 | 1 | 1 | 2009 |
1 organizations
Page 1 / 1